It Seems Gevo, Inc. (GEVO) Will Go Down. Just Reaches Yearly Low

April 22, 2018 - By Clifton Ray

Gevo, Inc. (NASDAQ:GEVO) Logo

The stock of Gevo, Inc. (NASDAQ:GEVO) hit a new 52-week low and has $0.32 target or 7.00 % below today’s $0.34 share price. The 9 months bearish chart indicates high risk for the $7.72M company. The 1-year low was reported on Apr, 22 by If the $0.32 price target is reached, the company will be worth $540,330 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.29% or $0.019 during the last trading session, reaching $0.34. About 341,841 shares traded. Gevo, Inc. (NASDAQ:GEVO) has declined 60.16% since April 22, 2017 and is downtrending. It has underperformed by 71.71% the S&P500.

Analysts await Gevo, Inc. (NASDAQ:GEVO) to report earnings on May, 8. They expect $-0.24 EPS, up 64.71 % or $0.44 from last year’s $-0.68 per share. After $-0.26 actual EPS reported by Gevo, Inc. for the previous quarter, Wall Street now forecasts -7.69 % EPS growth.

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum products based on isobutanol produced from renewable feedstocks in the United States. The company has market cap of $7.72 million. It operates through two divisions, Gevo, Inc. and Gevo Development/Agri-Energy. It currently has negative earnings. The firm engages in the research and development, and production of isobutanol; development of its proprietary biocatalysts; production and sale of biojet fuel; and retrofit process of chemicals and biofuels.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: